Lipid-lowering therapies for cardiovascular disease prevention and management in primary care

Author/s: 
Nicolas Dugré, Adrienne J. Lindblad, Danielle Perry, G. Michael Allan, Émélie Braschi, Jamie Falk, Liesbeth Froentjes, Scott R. Garrison, Jessica E.M. Kirkwood, Christina S. Korownyk
Date Added: 
October 15, 2023
Journal/Publication: 
CFP
Publisher: 
College of Family Physicians of Canada
Publication Date: 
October 1, 2023
Issue: 
10
Volume: 
69
Pages: 
701-711
Type: 
Meta-analyses, Reviews, and Guidelines
Format: 
Article
DOI (1): 
10.46747/cfp.6910701
PMID (1): 
37833094

RPR Commentary

An analysis of the evidence of the impact of various lipid lowering strategies in cardiovascular events and mortality. James W. Mold, MD, MPH

Abstract

Objective: To assess the benefits and harms of lipid-lowering therapies used to prevent or manage cardiovascular disease including bile acid sequestrants (BAS), ezetimibe, fibrates, niacin, omega-3 supplements, proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, and statins.

Text Availability

Free full text